Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Common Equity (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Common Equity for 4 consecutive years, with $42.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity rose 47.52% to $42.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $42.5 million, a 47.52% increase, with the full-year FY2025 number at $42.5 million, up 47.52% from a year prior.
  • Common Equity was $42.5 million for Q4 2025 at Spruce Biosciences, up from $5.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $108.0 million in Q1 2023 to a low of $5.4 million in Q3 2025.
  • A 4-year average of $61.6 million and a median of $67.6 million in 2022 define the central range for Common Equity.
  • Biggest YoY gain for Common Equity was 47.52% in 2025; the steepest drop was 89.57% in 2025.
  • Spruce Biosciences' Common Equity stood at $68.5 million in 2022, then grew by 11.71% to $76.5 million in 2023, then crashed by 62.33% to $28.8 million in 2024, then surged by 47.52% to $42.5 million in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Common Equity are $42.5 million (Q4 2025), $5.4 million (Q3 2025), and $13.2 million (Q2 2025).